The Vanguard Group, Inc. has recently announced that it has increased stake in Edwards Lifesciences Corp (NYSE:EW) by 0.62%. After grabbing 49.08 million shares, the institutional investor is now in possession of 0.3 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 8.09% having worth around $3.74 billion. Moreover, BlackRock Fund Advisors increased its share by 0.3 million to have a control over 31.56 million shares. And Capital Research & Management Co raised its holdings to 3.24 million shares by acquiring 30.25 million shares or 4.99% of the stake.
Edwards Lifesciences Corp (EW) concluded trading on Wednesday at a closing price of $72.54, with 4.44 million shares of worth about $321.99 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -20.88% during that period and On Wednesday, January 24 the price saw a loss of about -3.06%. Currently the company’s common shares owned by public are about 608.30M shares, out of which, 596.90M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 197 times over the past 12 months. They bought 1,405,593 shares in 86 of the transactions. In 111 selling transactions, insiders dumped 1,256,134 shares.
Vanguard Total Stock Market ETF, Vanguard 500 Index Fund, and Vanguard Health Care Fund are the top 3 mutual funds which are holding stakes in Edwards Lifesciences Corp Vanguard Total Stock Market ETF is currently holding 19.06 million shares of worth totaling $1.45 billion. The company recently came buying 5818.0 shares which brought its stake up to 3.14% of the company’s outstanding shares. Vanguard 500 Index Fund sold 5483.0 shares, after which its hold over company’s outstanding shares shrunk to 2.44%, leaving 14.81 million shares with the mutual fund that have a worth of about $1.13 billion. Vanguard Health Care Fund, after buying 9.39 million shares, have now control over 1.55% of the stake in the company. It holds 0.0 shares of worth $715.69 million.
However, the stock later moved at a day high price of 75.19, or with a loss of -3.06%. Stock saw a price change of -1.73% in past 5 days and over the past one month there was a price change of -3.22%. Year-to-date (YTD), EW shares are showing a performance of -4.87% which decreased to -9.39% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $60.57 but also hit the highest price of $94.87 during that period. The average intraday trading volume for Edwards Lifesciences Corp shares is 4.54 million. The stock is currently trading -3.26% below its 20-day simple moving average (SMA20), while that difference is up 1.21% for SMA50 and it goes to -7.62% lower than SMA200.
The Vanguard Group, Inc. acquired 49.08 million shares of Edwards Lifesciences Corp having value of about $3.74 billion. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 0.3 million shares in the company valued at close to $21954303.54, or have control over 0.62% stake in the company. Edwards Lifesciences Corp (NYSE: EW) currently have 608.30M outstanding shares and institutions hold larger chunk of about 85.61% of that. Holding of mutual funds in the company is about 39.48% while other institutional holders and individual stake holders have control over 46.97% and 1.17% of the stake respectively.
The stock has a current market capitalization of $44.00B and its 3Y-monthly beta is at 1.03. PE ratio of stock for trailing 12 months is 31.02, while it has posted earnings per share of $2.34 in the same period. Its PEG reads 3.88 and has Quick Ratio of 2.45 while making debt-to-equity ratio of 0.10. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EW, volatility over the week remained 2.39% while standing at 2.13% over the month.
Analysts are in expectations that Edwards Lifesciences Corp (EW) stock would likely to be making an EPS of $0.64 in the current quarter, while forecast for next quarter EPS is $0.66 and it is $2.76 for next year. For the current quarter EPS, analysts have given the company a lowest target $0.62 which is $0.66 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $0.64 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 1.18% while it is estimated to increase by 9.89% in next year. EPS is likely to shrink at an annualized rate of 7.99% for next 5-years, compared to annual growth of 22.06% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Evercore ISI on January 04, 2024 offering an In-line rating for the stock and assigned a target price range of between $80 and $77 to it.
